← Back to list
05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
Act
by Dec 29, 2025
Effective date
Dec 29, 2025
Identified
Jun 19, 2026
Summary
Independence Blue Cross revised policy 05.00.74l for TENS devices effective 12/29/2025, clarifying medically necessary criteria for chronic pain (other than lower back pain) and experimental/investigational criteria. The policy REMOVED the requirement for demonstrating at least 50% pain reduction with objective evidence (e.g., decreased opioid usage, improved range of motion, VAS scores) as a continuation criterion after the initial trial period. Billing teams must update their prior authorization and claims review processes to align with the relaxed documentation requirements for continued TENS coverage.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
by Dec 29, 2025 · 6 steps
01Billing and clinical review teams must update prior authorization and claims adjudication protocols for TENS devices (E0720, E0730).
02Remove the requirement to request objective evidence of 50% pain reduction (decreased opioid usage, improved ROM, increased activity, VAS/Numeric Pain Intensity Scale improvement) for continuation coverage decisions after the 30-60 day trial.
03Update authorization templates to require only that the treating provider documents in the medical record that the patient is likely to derive significant therapeutic benefit from continuous TENS use.
04Train providers ordering TENS devices that they must still be the treating provider for the underlying condition.
05Ensure billing software reflects that supply utilization limits remain unchanged (A4595: max 12/year for 2-lead, 24/year for 4-lead; A4557: once per 12 months).
06Update internal guidelines and payer-facing documentation.
If missed: Failure to adopt these changes will result in inappropriate claim denials for otherwise medically necessary continued TENS coverage and potential member appeals.
Codes mentioned
E0720E0730A4556A4557A4558A4595A4630G89.12G89.18G89.21G89.29G89.3G89.4
Original notice
05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →MA05.006l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesMediumEffective Dec 29, 2025 · Medical Policy05.00.74l, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesLowEffective Dec 29, 2025 · Medical PolicyMA05.006k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesMediumEffective Oct 1, 2025 · Medical Policy05.00.74k, Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesLowEffective Oct 1, 2025 · Medical PolicyBrowse every Independence Blue Cross change in the policy list